ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 2165

Fertility Concerns in Adolescents and Young Adults Receiving Gonadotoxic Medications for Rheumatic Disease

SHAHD FARAJALLAH1, Katie Dunnock2, Qing Yu3, Sangeeta Sule4 and Tova Ronis4, 1Children's national hospital, Washington DC, 2George Washington University, washington dc, 3George Washington University, washington dc, DC, 4Children's National Hospital, Washington, DC

Meeting: ACR Convergence 2024

Keywords: Drug toxicity, Education, health behaviors, pregnancy, Surveys

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Date: Monday, November 18, 2024

Title: Patient Outcomes, Preferences, & Attitudes Poster III

Session Type: Poster Session C

Session Time: 10:30AM-12:30PM

Background/Purpose: Adolescents and young adults diagnosed with rheumatic diseases often require treatment with teratogenic and cytotoxic medications to effectively manage their conditions. While these therapies are crucial to treat life and organ-threatening conditions, they may cause premature gonadal failure, future infertility, or increase the risk of adverse pregnancy outcomes. Cancer patients receive similar treatments and research in the pediatric oncology population has shown that concerns about fertility significantly impact their health-related quality of life (HRQOL). This has never been evaluated in pediatric rheumatology patients, despite the shared use of cytotoxic medications. Understanding rheumatologic patient perspectives on fertility-related issues and their knowledge of preservation options is essential for comprehensive care. The primary objective of this study was to identify fertility concerns by conducting assessments of patient attitudes toward fertility in adolescents diagnosed with rheumatic diseases previously exposed to cytotoxic medications.

Methods: We conducted a prospective survey-based psychometric descriptive study for eligible pediatric patients in the rheumatology clinic who had received cyclophosphamide or mycophenolate treatment. The survey was based on a validated HRQOL survey designed to assess fertility concerns and desires for future parenthood in adolescent oncology patients. Two survey versions were provided to different age groups (12-14 years and over 15 years). Relevant data were collected from the electronic health record (EHR). Survey results were analyzed using descriptive statistics.

Results: A total of 30 patients participated, with 27 being above the age of 15 (Table 1). Most patients in both age groups expressed a desire to have biological children. Counseling about infertility was reported by approximately 70% (21) of patients, with EHR review indicating documentation of counseling for 77% (23) of patients, suggesting close accuracy in counseling documentation. Fertility preservation measures were not pursued in any of our patients. Survey results of reproductive health concerns are presented in Figure 1. There were no differences noted between males and females. Over 90% of patients above the age of 15 expressed a preference for their reproductive health-related concerns to be addressed by their physician. Qualitative analysis of free-text responses regarding feelings associated with potential infertility revealed several key themes, underscoring the emotional and psychological impact of fertility concerns, as summarized in Table 2.

Conclusion: Fertility concerns are prevalent among patients undergoing treatment for rheumatic diseases, yet counseling and preservation measures may be underutilized. Addressing these concerns through education, counseling, and support for fertility preservation could mitigate distress and enhance the quality of life for these patients. Further research could focus on developing targeted interventions including creating standardized guidelines for healthcare providers, increasing accessibility to fertility preservation options, and integrating multidisciplinary approaches to care.

Supporting image 1

Table 1: Patient Characteristics and Reproductive Health Data

Supporting image 2

Figure 1: Patient Reproductive Health Concerns

Supporting image 3

Table 2: Thematic Analysis of Patient Responses


Disclosures: S. FARAJALLAH: None; K. Dunnock: None; Q. Yu: None; S. Sule: None; T. Ronis: None.

To cite this abstract in AMA style:

FARAJALLAH S, Dunnock K, Yu Q, Sule S, Ronis T. Fertility Concerns in Adolescents and Young Adults Receiving Gonadotoxic Medications for Rheumatic Disease [abstract]. Arthritis Rheumatol. 2024; 76 (suppl 9). https://acrabstracts.org/abstract/fertility-concerns-in-adolescents-and-young-adults-receiving-gonadotoxic-medications-for-rheumatic-disease/. Accessed .
  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to ACR Convergence 2024

ACR Meeting Abstracts - https://acrabstracts.org/abstract/fertility-concerns-in-adolescents-and-young-adults-receiving-gonadotoxic-medications-for-rheumatic-disease/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology